Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

132.03 -4.81 (-3.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,352,412
Open 136.80
Bid (Size) 132.00 (1)
Ask (Size) 133.00 (2)
Prev. Close 136.84
Today's Range 131.63 - 137.32
52wk Range 128.51 - 238.00
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases. 
Via Benzinga
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. 
Via The Motley Fool

Performance

YTD
-12.0%
-12.0%
1 Month
-6.8%
-6.8%
3 Month
-12.1%
-12.1%
6 Month
-31.9%
-31.9%
1 Year
-38.5%
-38.5%

More News

Read More
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
From Biogen Inc.
Via GlobeNewswire
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
How Is The Market Feeling About Biogen?
Via Benzinga
Biogen Analysts Lower Their Forecasts After Q4 Results
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Via Benzinga
Forecasting The Future: 10 Analyst Projections For Biogen
Via Benzinga
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
From Biogen Inc.
Via GlobeNewswire
Indexes Swimming In Red Ink On Recession Fears
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
Via Benzinga
Stocks Plummet As Trade Partners Retaliate Against Tariffs
Via Talk Markets
Topics Government Stocks / Equities World Trade
Exposures Political Tariff
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Via StockStory
Synchronicity: Denying The Unexplainable
Via Talk Markets
Topics Stocks / Equities
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Via Benzinga
Biogen Stock Is Mutating Into a Value Play
Via MarketBeat
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Via Benzinga
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Via Benzinga
Top S&P500 movers in Wednesday's session
Via Chartmill
Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Via Chartmill

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 132.03
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 04/01/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 19.25B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.